Listing 3 - Actual negotiations

Indication:

​As an adjunct to diet to reduce triglyceride levels for adult patients with genetically confirmed or clinically diagnosed familial chylomicronemia syndrome (FCS) for whom standard triglyceride lowering therapies have been inadequate.

Indication:

For the acute treatment of migraine, with or without aura, in adults

Indication:

In combination with trastuzumab and chemotherapy for the neoadjuvant treatment of adult patients with early-stage HER2-positive breast cancer

Indication:

Chronic hand eczema

Indication:

Braftovi, in combination with cetuximab and mFOLFOX6, for the treatment of patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by a validated test

Indication:

For the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase (ALK+) gene rearrangement

Indication:

For the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) who have previously received 1 tyrosine kinase inhibitor (second line).

Indication:

In combination with rituximab and lenalidomide for the treatment of adult patients with grade 1, 2, or 3a relapsed or refractory follicular lymphoma.

Indication:

In combination with enzalutamide for the treatment of adult patients with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC).

Indication:

In combination with cetuximab and chemotherapy, for the treatment of patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by a validated test.